<DOC>
	<DOC>NCT02047890</DOC>
	<brief_summary>This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies.</brief_summary>
	<brief_title>Japanese BAY1000394 Monotherapy Phase I Study</brief_title>
	<detailed_description />
	<criteria>Japanese male or female subjects aged â‰¥20 years Eastern Cooperative Oncology Group (ECOG) performance status of 0 1 Life expectancy of at least 12 weeks Subjects with advanced, histologically or cytologically confirmed solid tumors, not amenable to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and if in the judgment of the investigator, experimental treatment is clinically and ethically acceptable At least 1 tumor lesion evaluable by computer tomography (CT) or scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Adequate bone marrow, liver, and renal functions Anticancer chemotherapy or immunotherapy within 4 weeks of study entry. Mitomycin C or nitrosoureas should not be given within 6 weeks of study entry. Radiotherapy to target lesions within 3 weeks prior to the first dose of study drug. Use of biological response modifiers, such as granulocyte colonystimulating factor (GCSF), within 3 weeks prior to the first dose of study drug. Symptomatic metastatic brain or meningeal tumors. Investigational drug treatment outside of this study during or within 4 weeks prior to study entry. Blood pressure &lt;100/60 mmHg or pulse &gt;100 BPM</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CDK inhibitor</keyword>
	<keyword>BAY1000394</keyword>
	<keyword>Advanced malignancies</keyword>
	<keyword>Japanese</keyword>
</DOC>